Key facts
- This page summarizes Eric Lefebvre's Form 4 filing for PLIANT THERAPEUTICS, INC. (PLRX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 19 Jan 2024, 17:18.
Eric Lefebvre - 17 Jan 2024 Form 4 Insider Report for PLIANT THERAPEUTICS, INC. (PLRX)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- PLRX
- Reported as of
- 17 Jan 2024
- Net transaction value
- -$177,383
- SEC form
- 4
- Accepted by SEC
- 19 Jan 2024, 17:18:57 UTC
- Prior SEC filing
- 19 Jul 2023
- Next SEC filing
- 24 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/Mike Ouimette, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric Lefebvre filed Form 4 for PLIANT THERAPEUTICS, INC. (PLRX) on 19 Jan 2024.
Change
- Previous filing in this sequence was filed on 19 Jul 2023.
- Current net transaction value: -$177,383.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PLRX
transaction
Common Stock
Sale
- Transaction value
- $177,383
- Shares
- -10,295
- Change %
- -6.2%
- Price
- $17.23
- Shares after
- 156,920
- Date
- 17 Jan 2024
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 1 footnote
Footnote F1
Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $16.33 to $17.90, inclusive, o between January 17, 2024 and January 18, 2024 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4.